RT-PCR方法检测细胞信号传导抑制因子-1(SOCS-1) mRNA在髓性白血病中的表达

Detection of SOCS-1 mRNA Expression by RT-PCR in the Patients with Myeloid Leukemia

为了研究细胞信号传导抑制因子(SOCS-1)在急性和慢性髓性白血病患者外周血中的表达并探讨其临床意义,用RT-PCR的方法检测急性和慢性白血病患者外周血单个核细胞中SOCS-1mRNA的表达,并将其表达与所有患者的病情进行了分析。结果显示在25例急性髓性白血病患者中4例SOCS-1mRNA表达阳性,阳性率16·00%,在25例慢性髓性白血病患者中11例SOCS-1mRNA表达阳性,阳性率44.00%,二者差异有统计学意义。在25例慢性髓性白血病患者中,无进展组(慢性期)12例,阳性2例,而进展组(加速期和急变期)13例,阳性11例,两组间差异有统计学意义。SOCS-1mRNA阳性的CML患者,对干扰素治疗反应差,进入加速期后SOCS-1mRNA多数呈持续阳性表达,病情进行性发展,预后极差。结论急性和慢性髓性白血病患者外周血单个核细胞中均可检测到SOCS-1mRNA的表达,CML患者阳性率高,加速期与急变期表达阳性者显著增多,与干扰素治疗反应及预后密切相关。

In order to investigate the suppressor of cytokine signaling-1 （ SOCS-1 ） expression in peripheral blood mononuclear cells（PBMNC） of patients with acute and chronic myeloid leukemia and analyze its clinical significance, RT-PCR method was used for detecting SOCS-1 mRNA expression in PBMNC of 50 newly diagnosed patients. The result showed that positive expressions of SOCS-1 were observed in 4 of 25 patients with AML （ 16.00% ）, in 11 of 25 patients with CML （44.00%） and none in 10 normal controls. The differences between patients with AML and normal controls, and between patients with CML and normal controls were statistically significant. In CML group, 2 out of 12 cases with non-progression （chronic phase）, 9 of 13 cases with progression showed the positive expression, the difference between two subgroups was statistically significant. Those CML patients with SOCS-1 mRNA expression had poor response to IFN-α. When they transformed into accelerated phase, SOCS-1 mRNA expression was more persistently and frequently observed, and no response to IFN-α was observed. Most of them had very poor prognosis. It is concluded that the SOCS-1 mRNA can be detected in the PBMNC of the patients with acute and chronic myeloid leukemia. The SOCS-1 mRNA expression in the patients with CML is higher than that in patients with AML, and it is higher in accelerated phase and blast crisis significantly. This phenomenon is highly related to the reaction of IFN-α and prognosis.